List of seven medical conditions that could exempt you from paying any council tax
People with certain medical conditions could receive a partial or complete reduction in their council tax bill. Being eligible for a council tax reduction could see households save hundreds of pounds each year.
According to MoneySavingExpert (MSE), hundreds of thousands of people in England, Scotland and Wales could be entitled to this reduction and not claiming it.
It comes after council tax bills were put up in April, with almost all councils hiking bills by up to, or close to, the maximum rate permitted. On average, council tax bills have increased by 5.1% in the previous two years.
READ MORE: DWP confirms group that aren't eligible for Winter Fuel Payment under new rules
READ MORE: Record-breaking footballer and TV sports star opens HMO in Oldham
Since April 1, the average annual band D bill - the standard measure of council tax - is £2,280 a year in total. That's an increase of £109 from last year and a 20% rise from five years ago when the average bill was £1,898.
Join the Manchester Evening News WhatsApp group HERE
But people who are classed as "severely mentally impaired" may be able to claim up to 50% off their bill - or in the most severe cases have the whole bill wiped entirely.
According to the government, there are two criteria a person needs to meet to qualify for the discount:
they must have a certificate from a medical professional, such as a GP, to say they are "severely mentally impaired"
they must be able to prove they are claiming certain benefits
The government does not define what it means by "severely mentally impaired" but MSE suggests there are several conditions that may qualify for the discount.
According to MSE, the following conditions may qualify:
Dementia (including Alzheimer's)
Parkinson's
Severe learning difficulties
Multiple sclerosis
Cerebral palsy
Severe stroke
Schizophrenia
However, whether the discount is granted or not will depend on an individual's own circumstances and a diagnosis of one of the above does not necessarily mean the discount will be granted.
MSE explains: "You can be diagnosed as SMI as a result of a range of conditions – which could include things like dementia, Schizophrenia, multiple sclerosis, having had a stroke, or having had an accident which permanently affects your intelligence and social functioning.
"Many conditions can underlie being SMI, but no condition means a person is definitely also SMI. Being SMI is a doctor's diagnosis in its own right."
To qualify for the discount, a doctor must provide a certificate confirming that the patient is "severely mentally impaired".
According to the law, a person may be classed as such if they have "a severe impairment of intelligence and social functioning (however caused) which appears to be permanent".
To qualify for the discount you must also be able to prove you are claiming certain benefits, or in some cases, just that you are eligible for them.
Qualifying benefits may include:
Attendance Allowance
Universal Credit
Disability Living Allowance
Income Support
Personal Independence Payment
Further information can be found on the gov.uk website and local authorities can provide full eligibility criteria for the discount on their websites.
If you live on your own then your council tax discount will be 100% - meaning you won't have to pay any council tax.
You may get 50% off your council tax bill if you only live with people who are 'disregarded' from council tax - people who are not counted when working out how many people are in a household, including people under 18, people on certain apprenticeship schemes, full-time students, live-in carers and diplomats.
If you live with one other person who is not discounted then you can get a 25% discount.
You may also be able to get back payments, depending on which local council you pay your tax to.
According to MSE, some councils will backdate the discount by six years but each council has its own policy and they are not legally obliged to backdate the discount.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
6 hours ago
- Miami Herald
Biking might help lower risk of dementia
Want to reduce your risk of dementia and Alzheimer's disease? Get on your bike and ride, a new study recommends. Biking regularly for transportation appears to lower risk of dementia by 19% and Alzheimer's by 22%, according to results published Tuesday in JAMA Network Open. The results also suggest that cycling might even help increase the size of a brain region important for memory, researchers noted. "Cycling is a moderate- to high-intensity workout, and also requires balance," said Dr. Liron Sinvani, director of geriatric services at Northwell Health in Manhasset, N.Y., who reviewed the findings. "It requires more complex brain function than walking, which is why maybe it was a better reducer of dementia risk." "It's not about just doing exercise and making that part of your routine, but thinking about the way you live your life," she added in a news release. "So instead of having to drive somewhere, taking that bike and using active travel modes to get around as part of your lifestyle becomes very important." For the study, researchers analyzed data on nearly 480,000 people participating in the UK Biobank, a long-term health study of people living in England, Scotland and Wales. As part of the study, participants noted the forms of transport they used most often to get about, not including travel to and from work. During an average follow-up of 13 years, more than 8,800 participants developed dementia and nearly 4,000 developed Alzheimer's. Results showed a lower risk for dementia and Alzheimer's among those who cycled or included cycling among other forms of travel like walking, driving or using public transportation. "Our findings suggest that promoting active travel strategies, particularly cycling, may be associated with lower dementia risk among middle-aged and older adults, which carries substantial public health benefits by encouraging accessible, sustainable practices for cognitive health preservation," concluded the research team led by Liangkai Chen, an associate professor at Tongji Medical College at the Huazhong University of Science and Technology in Wuhan, China. MRI brain scans showed that cycling also was associated with a larger hippocampus, a part of the brain involved in memory formation and learning, researchers noted. However, cycling's benefits appeared to extend mostly to people without a genetic risk for Alzheimer's, results showed. People without the APOE E4 genetic variant had a 26% lower risk of dementia and 25% lower risk of Alzheimer's. Results were not statistically significant among APOE E4 carriers, but indicated less protection from cycling. Interestingly, the results also indicate that driving offered some protection against dementia compared to taking the bus or subway. "Even when using inactive travel like car or public transportation, it seemed like driving had a little bit better impact [on brain health] than public transportation," Sinvani said in the news release. However, researchers noted that this observational study could not draw a direct cause-and-effect link between cycling and healthy brain aging. "What I tell my patients and family and friends whenever they ask me what they can do to reduce their risk of dementia, is whatever gets you outside doing stuff is what you should be doing," she said. "I think we see that it's not just the physical activity, but it's also in the balance, and it really engages different parts of your brain." If you're able to get on a bike, Sinvani said, do that. If you're aren't, use your feet. "I think if it's, 'should I walk or take a bike?' I would say take a bike, but if it's 'should I walk or just stay home?' I would say definitely walk," she said. More information The U.S. Centers for Disease Control and Prevention has more on how physical activity boosts brain health. Copyright © 2025 HealthDay. All rights reserved. Copyright 2025 UPI News Corporation. All Rights Reserved.
Yahoo
8 hours ago
- Yahoo
New Analysis Finds Dementia Caregivers More Likely to Report Modifiable Risk Factors That Increase Their Own Risk for Dementia
– Dementia caregivers under age 45 are particularly vulnerable for having modifiable risk factors for dementia – CHICAGO, June 12, 2025 /PRNewswire/ -- A new analysis finds nearly 60% of dementia caregivers report having at least one modifiable risk factor that could increase their own chances of developing dementia. Nearly one in four caregivers (24.3%) report having multiple risk factors. This first-of-its-kind analysis found that dementia caregivers are significantly more likely than the general population to experience conditions such as obesity, diabetes, poor sleep, smoking and hypertension. The most pronounced differences were seen in smoking (caregivers were 30% more likely), hypertension (27% more likely), and poor sleep (21% more likely). Additionally, caregivers were 12% more likely to have diabetes and 8% more likely to be obese. Physical inactivity was the only one of the six modifiable risk factors examined for which dementia caregivers reported being less likely to engage in than the general population (9% less likely). "This analysis underscores the vulnerability of dementia caregivers," said Matthew Baumgart, senior vice president, Health Policy, Alzheimer's Association. "Dementia caregivers are often so busy caring for a family member or friend that they overlook their own health. This analysis should be a wake-up call for public health to develop strategies that address caregiver health to help this at-risk population." The analysis, conducted by the Public Health Center of Excellence on Dementia Risk Reduction at the Alzheimer's Association and the Public Health Center of Excellence on Dementia Caregiving at the University of Minnesota, found that younger dementia caregivers (under age 45) are particularly vulnerable to having modifiable risk factors for dementia. It found: Younger dementia caregivers are 40% more likely to have multiple risk factors (21.6% versus 15.5%) compared with all adults in their age group. Younger dementia caregivers were also 86% more likely to smoke, 46% more likely to have hypertension, and 29% more likely to report less than 6 hours of sleep per night on average compared with all adults in their age group. "By identifying elevated risk factors for dementia among certain dementia caregiving populations compared with the overall population, public health policymakers can prioritize and tailor resources and interventions accordingly," Joseph Gaugler, Ph.D., University of Minnesota School of Public Health. "Younger dementia caregivers, as well as American Indian/Alaska Native, Black, and male dementia caregivers, are all distinctly more likely to have conditions or behaviors that put them at greater long-term risk for cognitive decline and could benefit from additional attention." Previous studies have shown that caring for a person with Alzheimer's disease or another dementia can create new, or worsen existing, health problems for caregivers. More than 1 in 3 dementia caregivers say their health has gotten worse due to their care responsibilities, and more than a quarter of dementia caregivers delay or do not do things they should to maintain their health. The new analysis aims to spur public health agencies to address caregiver health and reduce the risk of dementia among caregivers. The new analysis examined data from the 2021-2022 Behavioral Risk Factor Surveillance System (BRFSS) to determine if dementia caregivers are more likely than the general population to have modifiable risk factors associated with dementia. Caregiving data from 47 states were included in the analysis. This work is supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of financial assistance awards totaling $6,307,435 with 100 percent funded by CDC/HHS. The contents are those of the Alzheimer's Association and the University of Minnesota and do not necessarily represent the official views of, nor an endorsement by, CDC/HHS, or the U.S. Government. About the Public Health Center of Excellence on Dementia Risk ReductionThe Public Health Center of Excellence on Dementia Risk Reduction translates the latest science on dementia risk reduction into actionable tools, materials and messaging that public health agencies can use. For more information visit or email CenterofExcellence@ About the Public Health Center of Excellence on Dementia CaregivingThe Public Health Center of Excellence on Dementia Caregiving offers technical guidance to, curates and distributes resources for, and brings together public health agencies, service organizations, healthcare providers, and dementia caregivers. For more information visit View original content to download multimedia: SOURCE Alzheimer's Association Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
8 hours ago
- Business Wire
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role. 'Richard has made tremendous contributions to Ionis over his 30-year tenure during which he spearheaded dozens of development programs and brought six innovative medicines through regulatory approvals, including TRYNGOLZA, our first independent commercial medicine. We thank him for his leadership and unwavering dedication to patients in need,' said Brett P. Monia, Ph.D., chief executive officer, Ionis. 'Holly is a deeply respected and innovative leader who will champion our vision to bring a steady cadence of transformational medicines to people in need and support Ionis' continued growth as a fully integrated biotechnology company. Her broad experience across research and development, strong operational and management skills, and deep neurology expertise, position Holly to successfully guide our portfolio, which includes eight wholly owned neurology medicines in clinical development.' Dr. Kordasiewicz has 20 years of experience in research and development and joined Ionis in 2011. An expert in neurology drug development, she currently oversees Ionis' industry-leading neurology program, including medicines for Alexander disease, Angelman syndrome, Alzheimer's disease, prion disease and multiple system atrophy. Dr. Kordasiewicz also played an integral role in the discovery and development of our Biogen-partnered programs QALSODY ® (tofersen) for a genetic form of amyotrophic lateral sclerosis and IONIS-MAPT Rx (BIIB080), a promising Alzheimer's disease medicine in Phase 2 development. Dr. Kordasiewicz holds a B.A. from SUNY-Geneseo and a Ph.D. in Neuroscience from the University of Minnesota. She completed postdoctoral work at the University of Minnesota and the University of California San Diego. Dr. Geary joined Ionis in 1995 and has been involved in nearly every aspect of discovery and development. Under Dr. Geary's leadership, Ionis submitted more than 50 investigational new drug applications to regulatory agencies and achieved six FDA and EU approvals, including TRYNGOLZA ® (olezarsen). Dr. Geary will serve as a strategic consultant to Ionis throughout 2026 to support a seamless transition. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit and follow us on X (Twitter), LinkedIn and Instagram. Ionis Forward-looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2024, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals ® and TRYNGOLZA ® are trademarks of Ionis Pharmaceuticals, Inc. QALSODY ® is a registered trademark of Biogen.
